Related Experiment Videos
[Fentanyl-TTS for postoperative pain therapy. A new alternative?]
1Universitätsklinik für Anaesthesiologie, Intensiv- und Schmerztherapie, Bergmannsheil Bochum.
Der Anaesthesist
|May 1, 1993
Summary
Fentanyl Transdermal Therapeutic System (Fentanyl-TTS) offers continuous postoperative pain relief for 72 hours. While effective after an initial lag period, it carries risks of respiratory depression and common side effects like nausea and sedation.
Area of Science:
- Pharmacology
- Anesthesiology
- Pain Management
Context:
- Postoperative pain management often relies on insufficient systemic analgesics or regional techniques.
- Fentanyl Transdermal Therapeutic System (Fentanyl-TTS) presents a novel approach for sustained postoperative pain control.
Purpose:
- To evaluate the efficacy and safety of Fentanyl-TTS in managing postoperative pain.
- To assess the pharmacokinetic profile and adverse event incidence of Fentanyl-TTS.
Summary:
- Fentanyl-TTS provides continuous fentanyl release for 72 hours, achieving therapeutic serum levels within 8-16 hours.
- Efficacy was demonstrated, with significantly reduced analgesic requirements after the initial 12-hour lag phase and for 12 hours post-removal.
- Adverse events included respiratory depression in up to 9% of patients, nausea (62%), vomiting (26%), and sedation (22%).
Impact:
- Fentanyl-TTS offers a viable option for prolonged postoperative pain management, though careful monitoring for side effects is crucial.
- The transdermal system's delayed onset necessitates supplementary analgesia during the initial treatment phase.
- Understanding the pharmacokinetic profile and adverse event rates is vital for optimizing patient care and safety.